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Abstract
Objective
Gaucher disease (GD) is a rare inborn error of metabolism, classified 
as a lipid storage disorders. This disease is caused by a deficiency in 
glucocerebrosidase enzyme. It has been classified according to the 
presence or absence of neurological symptoms into the following types: 
type 1 non-neuropathic, type 2 acute infantile neuropathic and type 3 or 
chronic neuropathic. We evaluated neurological symptoms in patients with 
GD1 and GD3 and compared both of these groups.
Materials & Methods
Eleven patients were identified according to their clinical presentation and 
the presence of disease confirmed by genetic testing, from 2006-2016, at the 
Mofid Children Hospital Clinic, Tehran, Iran. We included eight patients 
with GD 1 and three patients with GD3. Careful neurological examination 
was performed on these patients during treatment by pediatric neurologist.
Results
Patients with GD1 had some neurological symptoms including cognitive 
impairment, developmental disability, behavioral disorder, microcephaly 
and increased deep tendon reflexes (DTR). Of course, neurological signs 
in patients with type 3 of GD were different and were included seizures, 
supranuclear gaze palsy, cerebellar signs, and ataxia. 
Conclusion
The current nomenclature for 3 types of Gaucher disease does not meet all 
clinical symptoms. Patients with GD1 display many neurological deficits 
in young ages not reported adequately earlier.
Keywords: Neurological symptom; Gaucher type 1; Gaucher type 3; 
Glucocerebroside
Introduction
Gaucher disease (GD) is the most common disease of inborn  error of 
metabolism. It is an autosomal recessive lipid storage disorder, caused 
by a defect in the  gene that encodes β-glucocerebrosidase (GBA gene). 
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GBA gene is located on chromosome1q21. Almost 
300 mutations and polymorphisms in GBA have 
been identified. Most cases are point mutations, 
insertions, and deletions; splice site alterations and 
recombination alleles have also been identified (1). 
Four mutations  account for over 90% of disease 
alleles. The allele mutations N370S, 84GG, L444P, 
and IVS2+1Gare are common in Ashkenazi Jewish 
patients (2). Non-Jewish patients exhibit a wider 
range of genotypes, although two  mutations 
including N370S and L444P are common in 
both populations (3). Defect in GBA induced 
accumulation of glucocerebroside in the spleen, 
bone marrow, liver, brain, and lungs (4, 5). 
The onset of disease in type 1 may vary from 
early childhood to adulthood. Symptoms such 
as  bone pain, bone fractures, splenomegaly, 
hepatomegaly, and cytopenia (anemia, leukopenia 
or thrombocytopenia) are common. GD1 is the 
most common type of this disease. In type 1 of GD, 
symptoms may not be clinically significant until 
adulthood. These patients usually present with easy 
bruises due to thrombocytopenia, fatigue due to 
anemia, and recurrent infections due to leukopenia. 
Other abnormalities may also be present, such as 
abdominal distention or abdominal discomfort due 
to organomegaly and skeletal disorders such as 
osteopenia, lytic bone lesions, pathological bone 
fractures, chronic bone pain, bone crisis, bone 
infarcts, osteonecrosis and skeletal deformities 
(1). GD1 has been named non-neuropathic form. 
However, in past studies, neurologic symptoms 
have been reported in non-neuropathic GD, too. For 
example  in one study, neurological deficits were 
mentioned in 30.7% of these patients and included 
on dementia, psychomotor delay, Parkinsonism, 
impaired saccadic eye movements and peripheral 
neuropathy (6).
However, another study reported experiences on 
neurological manifestations of non-neuropathic 
Gaucher’s disease and concluded recent data may 
discuss on Gaucher’s classification and suggest 
the existence of a continuum between neuropathic 
and non- neuropathic forms of the GD disease (7). 
Another study reported neurologic complications 
in patients with type 1 of Gaucher’s disease, but 
secondary to systemic features of the illness, such 
as coagulopathy, or skeletal disease (8). GD2, acute 
infantile neuropathic form of this disease, manifests 
as severe neurological deficits that appear around 3 
months of age and patients usually die before 2 yr 
of age not discussed in our study (9).
In GD3, the most common symptoms are skeletal 
abnormalities, eye movement disorders, respiratory 
problems, blood disorders and brain involvement. 
The brain abnormalities manifest gradually,  as 
seizures, cognitive deficits, and poor coordination. 
Eye movement abnormalities, such as horizontal 
saccadic eye movements, have also been reported 
in type 3 (10). 
In this study, we evaluated neurological symptoms 
in the patients with GD1 and GD3 and compared 
both of these groups.
Materials & Methods
Patients with symptoms suggestive of Gaucher 
disease were screened, selected and followed 
over a period of 10 yr (since Oct 2006 until 
Nov 2016) at the Mofid Children Hospital 
Clinic in Tehran, Iran. The clinical deficits of 
these patients manifested by blood disorders, 
skeletal involvement, organomegaly, respiratory 
problems and/or neurological involvement such 
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as seizures, cognitive deficit, poor coordination, 
ataxia, developmental disability, nuclear gaze 
palsy, oculomotor apraxia and so on. In addition 
to identifying these patients by their clinical 
manifestations, β-glucocerebrosidase activity 
on leukocytes and fibroblasts was determined 
by enzyme assay in wagnester laboratory in 
German. β-Glucocerebrosidase is an enzyme with 
glucosylceramidase activity cleaved by hydrolysis, 
the beta-glucosidic linkage of the chemical 
glucocerebroside, an intermediate in glycolipid 
metabolism (11).
After identifying the patients with 
β-glucocerebrosidase deficiency, genetic testing 
was performed to confirm diagnosis. A complete 
physical exam, including a delicate neurological 
assessment, was performed by Pediatric Neurologist 
in the Clinic of Mofid Children Hospital. We also 
recorded the cognitive and developmental status, 
behavioral disorders and any seizure activity. In 
physical examination, head circumference, eye 
movement abnormalities such as strabismus, gaze 
palsy, oculomotor apraxia, cerebellar function, and 
DTR were evaluated. Developmental status was 
assessed by Denver 2 test; cerebellar function was 
evaluated by clinical tests such as tandem gait, 
finger to nose, heel to shin, dysdiadochokinesia 
and so on. 
The data were analyzed by descriptive methods and 
no statistical testing was applied as observational 
study.
Results
Eleven patients with the diagnosis of GD1 (8 
patients) and GD3 (3 patients) were included. 
The enzymatic study showed decreased 
β-Glucocerebrosidase activity and diagnosis was 
further confirmed by genetic testing (Table 1).
Table 1.  The result of B glucocerebrosidase enzyme activity
N
Type of 
disorder
Genotype Glucocerebrosidase activity Chitotriosidase activity
1 1 M416r/- 2 3070
2 1 M416r/- 1.3 3202
3 1 Homozygote l354v 4.47
4 1 R163q/r163q + n188s/n188s 3.59 2947.5
5 1 Homozygote s400g 0.7 8048.4
6 1 M416r/- 1.3 2062
7 1 M416r/- 1.9 11577
8 1 Homozygote l444p 1.77 3483.9
9 3 Homozygote l444p 1.93 38131
10 3 Homozygotel444p/l444p 2.8 6213
11 3 Homozygotell444p/l444p 6.17 2381
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Eight patients had GD1, and three had GD3. Seven 
of these patients were female. The mean age of 
patients was 9.95 yr. The patient’s  ages ranged 
from 5-30 yr old with the mean age at the time of 
diagnosis being 4.36 yr. All of patients had parents 
with consanguinity of marriage. Parents were first 
cousin in ten patients and second cousin in one 
case. Three patients had a positive family history 
of similar diseases.
Chief complaints expressed by GD1 patients at 
the time of presentation consisted as follows: 
Abdominal distention and discomfort due to 
hepatosplenomegaly were seen in 75% of patients, 
epistaxis due to thrombocytopenia in 25% of 
patients, anorexia and weight loss in 25%, also, 
limb pain with difficulty walking in one patient. 
Chief complaints in primary presentation of 
patients with GD3 were similar to patients with 
GD1, with hepatosplenomegaly in all of GD3 
patients, epistaxis in one patient, and anorexia and 
weight loss in two patients. Additionally, there was 
delay in teeth growth in all of them.
Neurological problems  were detected in all of 
eight patients with GD1 and included: cognitive 
impairment in one patient (13%), developmental 
delay and microcephaly in four patients (50%), 
behavioral disorder, mild spasticity and increased 
DTR in three patients (in 37%). 
On the other hand, neurological findings in three 
patients with GD3 were developmental delay in 
all of them as well as cerebellar  dysfunction, and 
disrupted Trendelenburg test in all cases, ataxic gait, 
the behavioral disorder, myoclonic seizure in one 
patient. Abnormal eye movements were noticeable 
in all of the patients with GD3 with convergence 
esotropia and disrupted saccadic eye movement in 
one case, esotropia with high pressure in eyes with 
corrected surgery in one patient, and disrupted 
saccadic eye movement in horizontal direction and 
upward gaze in another case.
Discussion
We found that all of patients with GD1 presented 
with abdominal distention and discomfort 
due to hepatosplenomegaly, epistaxis due to 
thrombocytopenia, anorexia, weight loss and limb 
pain. Only one patient manifested with impaired 
walking. The chief clinical finding in patients with 
GD3 was similar to patients with GD1, contains 
hepatosplenomegaly, epistaxis, anorexia and 
weight loss, as well as a delay in teeth, grow in all 
of three patients.
Three types of GD have been reported. The 
most prevalent is type 1 or non-neuropathic with 
prominent abnormalities such as thrombocytopenia, 
anemia, organomegaly and skeletal abnormalities, 
that our patients presented these symptoms, too. 
Type 2 GD, or acute neuropathic, with a poor 
prognosis and survival (12). In addition, GD type3, 
in these type neurological symptoms, commonly 
manifest late in life as compared to type 2, and 
include abnormal eye movements, ataxia, seizures, 
and dementia, and patients live until their third 
or fourth decade of life (13-15). Our patients 
with GD3 presented by hepatosplenomegaly, 
thrombocytopenia, anemia, skeletal muscle 
dysfunction plus central neurological involvement.
Neurological problems in our patients with GD3 
included developmental delay, behavioral disorder, 
myoclonic seizure, and cerebellar dysfunction; 
disrupted Trendelenburg test and abnormal eye 
movements. Ataxic gait in one patient, convergence 
esotropia and disrupted saccadic eye movements in 
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another case, high pressure in the eye with history of 
twice eye surgery for strabismus correction in one 
patient, as well as disrupted saccadic movements 
in the horizontal and upward direction identified in 
another case.
Dysfunction of horizontal saccadic eye movement, 
brainstem bleeding or glioma has been reported 
commonly in type 3 of more gauche disease. 
Impairment of horizontal and vertical saccadic eye 
movement is seen in later stages of GD type 3 or 
Niemman pick type C (7). GD3 can be presented 
by complex cerebellar symptoms such as cerebellar 
ataxia, intention tremor and Progressive myoclonic 
epilepsies (PMEs) (16-18). 
In our study, patients with GD1 presented with a 
variety of neurological problems such as cognitive 
impairment in one case, developmental delay 
and microcephaly in 4 patients (50%), behavioral 
disorder, mild spasticity and increased DTR 
in 3 patients in mean age of 9.95 yr. Cognitive 
impairment, Parkinsonism, tremor and gait 
impairment in GD 1 are reported (19). Patients 
with GD type 1 might develop some late-onset 
neurological deficits (4). Neurological problems 
have been reported in 30.7% of patients with 
GD1 in adulthood, and included on: dementia, 
psychomotor delay, Parkinsonism (6).
Most of previous studies have been done in adult 
patients, so they often noticed early dementia and 
Parkinsonism in neurological presentation of their 
GD1 patients, but we studied on children and mean 
age of our patients at the bingeing of assessment 
was 4.36 yr, so our patients presented with different 
pattern with spasticity, developmental delay, 
microcephaly, and so on.
Another study reported neurologic complications 
in patients with GD1 secondary to systemic 
features of the illness, such as CNS bleeding due to 
coagulopathy, or abnormal gait induced by skeletal 
disease (8). However, our patients had spasticity, 
increased DTR, microcephaly and other signs that 
were not justified by primary problems such as 
coagulopathy, or skeletal disease.
Another study reported neurological manifestations 
of GD1 and according to recent information deducted 
that may discuss Gaucher’s classification and the 
existence of a continuum between neuropathic 
and non- neuropathic forms of the GD disease (7). 
Thus, according to our assessment, patients with 
GD1 have variety of neurological problems such 
as developmental delay, microcephaly, behavioral 
disorders, spasticity, and so on, although some kinds 
of neurological involvements such as myoclonic 
seizure, supranuclear gaze palsy, cerebellar sign, 
and ataxia, are more typically seen in GD3 patients.
However, unlike previous studies that mentioned 
GD type 3 and type 1 differentiated by existence 
of neurological involvements in type 3, we found 
that type 1 could also be presented with some 
neurological deficits. Therefore, the neurological 
symptoms are not the important criteria for 
differentiation between different types of more 
gauche disease, and genetic testing is required 
for confirmation of diagnosis and determining a 
treatment plan.
In Conclusion, current nomenclature for 3 types of 
Gaucher disease does not meet the clinical symptoms 
presented in all the patients. Patients with GD1 display 
many neurological deficits in young ages which less 
reported in prior studies. We certainly need further 
studies in larger populations to identify clearly more 
patients with the same deficits as what our study 
indicated. 
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